Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 14/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 11/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133031 | 0.82 | TRPA1 (0.53) | GRIN2BGRIN1TRPA1 | |
| SCHEMBL29901520 | 0.81 | GRIN2B (0.44) | GRIN2BGRIN1KCNH2TRPA1 | |
| SCHEMBL22775369 | 0.80 | GRIN2B (0.47) | GRIN2BGRIN1KCNH2TRPA1 | |
| SCHEMBL29901513 | 0.79 | GRIN2B (0.44) | GRIN2BGRIN1TRPA1 | |
| SCHEMBL22771356 | 0.78 | GRIN2B (0.51) | GRIN2BGRIN1KCNH2 | |
| SCHEMBL22774734 | 0.77 | GRIN2B (0.43) | GRIN2BGRIN1KCNH2TRPA1 | |
| SCHEMBL22775262 | 0.73 | GRIN2B (0.46) | GRIN2BGRIN1KCNH2 | |
| SCHEMBL22775892 | 0.73 | GRIN2B (0.48) | GRIN2BGRIN1KCNH2 | |
| SCHEMBL29901458 | 0.70 | GRIN2B (0.45) | GRIN2BGRIN1KCNH2TRPA1 | |
| SCHEMBL29901554 | 0.69 | GRIN2B (0.52) | GRIN2BGRIN1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | US | disclosed |
| US-20220274984-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045960-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885GRIN1 6/4885KCNH2 2725/4885 |
| US-20220274984-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | GRIN2B 1/4885GRIN1 6/4885KCNH2 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.